Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Plaque stabilization by LDL apheresis?].

P Schuff-Werner1, V Schettler

  • 1Institut für Klinische Chemie und Pathobiochemie, Medizinische Fakultät, Universität Rostock. pschuffw@med.uni-rostock.de

Herz
|March 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calpain mediates caspase-dependent apoptosis initiated by hydrogen peroxide in pancreatic acinar AR42J cells.

Free radical research·2013
Same author

How to optimize lipoprotein apheresis treatment--a second look.

Atherosclerosis. Supplements·2013
Same author

An erythropoietin gene polymorphism in the hypoxia-responsive element at position 3434 is possibly associated with hypertension.

Kidney & blood pressure research·2011
Same author

Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.

International journal of clinical practice·2010
Same author

[The European Register of specialists in clinical chemistry and laboratory medicine: code of conduct Version 2-2008].

Annales de biologie clinique·2010
Same author

[Effects of LDL-apheresis--more than reduction of cholesterol?].

Deutsche medizinische Wochenschrift (1946)·2007

Extracorporeal LDL-elimination rapidly stabilizes vulnerable plaques, significantly reducing atherothrombotic events like myocardial infarction. This LDL-apheresis therapy offers earlier clinical event reduction compared to drug therapy alone.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Interventional Cardiology

Context:

  • Vulnerable lipid-rich plaques are primary drivers of atherothrombotic events, including unstable angina and acute myocardial infarction.
  • Long-term low-density lipoprotein (LDL)-lowering therapies demonstrably stabilize plaques and reduce myocardial reinfarction rates.
  • Emerging evidence suggests extracorporeal LDL-elimination may offer earlier clinical event reduction than drug therapy alone.

Purpose:

  • To investigate the early effects of LDL-apheresis on vulnerable plaque regression and atherothrombotic event reduction.
  • To elucidate the mechanisms by which LDL-apheresis impacts plaque stability, vascular resistance, and coagulation.
  • To compare the efficacy of LDL-apheresis with conventional LDL-lowering drug therapy in managing high-risk cardiovascular patients.

Related Experiment Videos

Summary:

  • Regular extracorporeal LDL-elimination, achieving over 60% LDL reduction weekly, is associated with early regression of lipid-rich vascular lesions.
  • LDL-apheresis, particularly HELP and double filtration methods, reduces plasma viscosity and improves vasomotoric reserve, lowering peripheral arterial resistance and shear-stress on vulnerable plaques.
  • This procedure effectively removes oxidized LDL, mitigating inflammatory effects that hinder plaque stabilization, and normalizes hypercoagulable states by interacting with coagulation factors, thereby preventing atherothrombotic events.

Impact:

  • LDL-apheresis demonstrates potential for rapid plaque stabilization and significant reduction in atherothrombotic events, offering a promising therapeutic option for high-risk cardiovascular patients.
  • The early regression of lipid-rich lesions observed with LDL-apheresis suggests a faster therapeutic benefit compared to traditional long-term LDL-lowering strategies.
  • By addressing multiple pathophysiological mechanisms including LDL levels, inflammation, vascular resistance, and coagulation, LDL-apheresis provides a comprehensive approach to preventing recurrent cardiovascular events.